Akoya Biosciences Inc（AKYA）资讯与事件AKYAAkoya Biosciences Inc

Quanterix shareholder issues statement on Akoya Biosciences merger pact

Kent Lake, a holder of approximately 7.7% of the outstanding common stock of Quanterix (QTRX), issued the following statement regarding the company's announcement of an amended merger agreement related to its proposed merger with Akoya Biosciences (AKYA): "Quanterix's decision to press on with the Merger in the face of significant public shareholder opposition is bad enough. What is even more egregious is the fact that the Company will no longer provide shareholders with the opportunity to vote on the Merger. This shocking disenfranchisement indicates a blatant disregard for the will of shareholders and a complete lack of accountability on the part of the Company's Board of Directors - especially since vote reports showed the proposal for the Merger losing by a nearly 3-1 margin. In its press release yesterday, Quanterix Chief Executive Officer Masoud Toloue stated that "the strategic merits of the transaction remain strong." Unfortunately for Dr. Toloue, the steep decline in Quanterix's stock price and enterprise value - which are down 48% and over 100%, respectively, since the Merger was announced, tell a different story.2 If the Company truly believes in the merits of the transaction, why is it afraid to let shareholders vote on it? We believe that it is no longer possible to trust a Board that negotiated such a value-destructive transaction in the first place and that has now decided to ignore the concerns of major shareholders. Quanterix's directors have proven themselves unable to represent the best interests of shareholders. This situation makes the need for boardroom change even more pressing, and we will continue our efforts to elect the three highly qualified individuals we have nominated to the Board at this year's Annual Meeting. We look forward to communicating further in the weeks to come."

Quanterix, Akoya Biosciences announce amended merger agreement

Quanterix (QTRX) and Akoya Biosciences (AKYA) announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76M shares of its common stock and pay $20M in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. With the amended exchange ratio, Quanterix will issue over 9M fewer shares than under the original deal terms. Quanterix shareholders will own approximately 84% of the combined company and Akoya shareholders will own approximately 16%. The revised transaction terms and amended merger agreement have been approved by the Quanterix Board and the Akoya board, respectively. Shareholders of Akoya who hold more than 50% of Akoya's common stock have agreed to vote in favor of the merger on the amended terms. As a result of the amended merger agreement, Quanterix will no longer hold its previously announced special meeting of shareholders. The transaction is expected to close during the second quarter of 2025, subject to the approval of Akoya shareholders and satisfaction of other customary closing conditions.

Akoya expands portfolio with new ADC breast cancer assay at AACR 2025

Akoya Biosciences announced the availability of a new assay designed to advance antibody-drug conjugate development in breast cancer. The new assay will be featured alongside customer-generated real-world data from the PhenoCode Discovery IO60 panel-Akoya's flagship ultrahigh-plex immuno-oncology solution-at the American Association for Cancer Research, AACR, 2025 Annual Meeting, taking place April 25-30 in Chicago, Illinois.